Bristol Myers buys into Repertoire's autoimmune vaccines, giving new life to Flagship startup
Flagship-incubated Repertoire Immune Medicines has lined up an autoimmune disease pact with Bristol Myers Squibb, marking the first major update from the well-funded startup in about two years.
Bristol Myers will dish out $65 million upfront to the Cambridge, MA-based startup as they look to create so-called “tolerizing vaccines” for up to three undisclosed autoimmune diseases. The deal could balloon to $1.8 billion if all milestones are met, the companies said Monday morning.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.